Patient understanding of the treatment of their asthma across three continents and six countries
Results from the new multi-country Annual Asthma Patient Survey reveal ongoing gaps in asthma care despite patient confidence in their asthma control
Full study details and insights will be made available soon.
Technical note: On behalf of AstraZeneca, Ipsos conducted an online survey with 807 participants who chose to take part in the US (n=235), UK (n=108), Canada (n=54), Mexico (n=110), China (n=200) and Saudi Arabia (n=100). All participants are aged 18 years old or older, have been personally diagnosed with asthma by a healthcare professional (i.e., a doctor or nurse; NB doctor in France) and use an inhaler for their asthma. Those who used non-SABA inhalers were not eligible to take part in the study. No weighting has been applied to survey data. Quotas were set by type of inhalers used (SABA only, SABA + ICS, SABA + ICS LABA). Fieldwork took place from 21 February to 29 March 2022.
Full technical note available below.
